In p53 WT condition, MDM2-inhibitor therapy suppresses tumor invasiveness possibly through E2F → PEG10 → MMP pathway, while in the MDM2-amplified and p53 mutant group, MDM2-targeted therapy suppresses EMT signaling that leads to tumor regression. Here, MDM2 is linked to neoplasm.